Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 31, 2022 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 63 | 0 | — | — | 1997-07 |
| Luminespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 23 | 0 | — | — | 2007-07 |
| Dactolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 16 | 0 | — | — | Dec 21, 2006 |
| Pilaralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 13 | 0 | — | — | 2007-06 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 13 | 0 | — | — | 2008-07 |
| Conatumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2007-06 |
| Onalespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2008-05 |
| Pictilisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2007-10 |
| Bimiralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | 2014-01 |
| Eprenetapopt | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | 2009-05 |
| Foretinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | Mar 17, 2005 |
| Retaspimycin Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | 2005-06 |
| Apitolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2009-03 |
| Molibresib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | Mar 28, 2012 |
| Tamibarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2007-09 |
| Alvespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2004-06 |
| Sotrastaurin Acetate | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2009-04 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2008-04 |
| Tandutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2002-05 |
| Birabresib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Oct 23, 2014 |
| Duligotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Nov 9, 2010 |
| Galiximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2002-01 |
| MVT Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2016-01 |
| Onatasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Jul 20, 2010 |
| Refametinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Feb 5, 2013 |
| 7-Ethyl-10-Hydroxycamptothecin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2007-03 |
| Bafetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-07 |
| MEK-1/MEKK-1 Inhibitor E6201 | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Jun 22, 2008 |
| Quarfloxin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2005-07 |
| Rebastinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2009-03 |
| Triciribine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2006-04 |
| 2-Deoxy-D-glucose | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-02 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 19, 2013 |
| Bone Marrow Transplantation | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-08 |
| Canertinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-12 |
| Lumretuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-12 |
| MUC1-targeted Peptide GO-203-2C | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-01 |
| Multikinase Inhibitor AEE788 | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2003-07 |
| Pemrametostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Aug 30, 2016 |
| Porcupine Inhibitor WNT974 | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 1, 2011 |
| Tarextumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2010-12 |
| Amuvatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-05 |
| Bazedoxifene | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 9, 2015 |
| Cetuximab/Irinotecan Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-08 |
| HER2 Inhibitor CP-724,714 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-01 |
| Lometrexol | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-09 |
| MEK Inhibitor CI-1040 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-01 |
| Salirasib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-05 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 23, 2017 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.